Cargando…

Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies

AIMS: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain. METHODS: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary car...

Descripción completa

Detalles Bibliográficos
Autores principales: Anguita, Manuel, de la Figuera, Mariano, Cabeza, Alejandro I Pérez, Fernández, Carmen Suarez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822684/
https://www.ncbi.nlm.nih.gov/pubmed/31692949
http://dx.doi.org/10.7573/dic.212606
_version_ 1783464383295258624
author Anguita, Manuel
de la Figuera, Mariano
Cabeza, Alejandro I Pérez
Fernández, Carmen Suarez
author_facet Anguita, Manuel
de la Figuera, Mariano
Cabeza, Alejandro I Pérez
Fernández, Carmen Suarez
author_sort Anguita, Manuel
collection PubMed
description AIMS: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain. METHODS: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary care; n=133), SILVER-AP (primary care; n=457), ALADIN (internal medicine and neurology; n=249), and ESPARTA (internal medicine; n=110) of patients taking rivaroxaban were analyzed. The clinical profile was compared with those of the XANTUS and ROCKET-AF studies. RESULTS: Overall, mean age was 74.9±9.4 years, CHA(2)DS(2)-VASc score was 3.7±1.5, and 43.2% had a HAS-BLED score ≥3. Patients included in the HEROIC and EMIR studies were older and more frequently had a creatinine clearance <50 mL/min and a higher thromboembolic risk than those in the XANTUS study, and patients included in the ALADIN study were older and had more prior cerebrovascular disease, but a lower thromboembolic risk than those in the ROCKET-AF trial. In those studies with available data, medication adherence and satisfaction with rivaroxaban were high. CONCLUSION: Bearing in mind differences according to the clinical setting of each study, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk. Medication adherence and satisfaction with rivaroxaban were high.
format Online
Article
Text
id pubmed-6822684
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-68226842019-11-05 Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies Anguita, Manuel de la Figuera, Mariano Cabeza, Alejandro I Pérez Fernández, Carmen Suarez Drugs Context Original Research AIMS: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain. METHODS: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary care; n=133), SILVER-AP (primary care; n=457), ALADIN (internal medicine and neurology; n=249), and ESPARTA (internal medicine; n=110) of patients taking rivaroxaban were analyzed. The clinical profile was compared with those of the XANTUS and ROCKET-AF studies. RESULTS: Overall, mean age was 74.9±9.4 years, CHA(2)DS(2)-VASc score was 3.7±1.5, and 43.2% had a HAS-BLED score ≥3. Patients included in the HEROIC and EMIR studies were older and more frequently had a creatinine clearance <50 mL/min and a higher thromboembolic risk than those in the XANTUS study, and patients included in the ALADIN study were older and had more prior cerebrovascular disease, but a lower thromboembolic risk than those in the ROCKET-AF trial. In those studies with available data, medication adherence and satisfaction with rivaroxaban were high. CONCLUSION: Bearing in mind differences according to the clinical setting of each study, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk. Medication adherence and satisfaction with rivaroxaban were high. BioExcel Publishing Ltd 2019-10-09 /pmc/articles/PMC6822684/ /pubmed/31692949 http://dx.doi.org/10.7573/dic.212606 Text en Copyright © 2019 Anguita M, de la Figuera M, Pérez Cabeza AI, Suarez Fernández C. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Original Research
Anguita, Manuel
de la Figuera, Mariano
Cabeza, Alejandro I Pérez
Fernández, Carmen Suarez
Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
title Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
title_full Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
title_fullStr Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
title_full_unstemmed Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
title_short Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
title_sort clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in spain: data from six nationwide studies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822684/
https://www.ncbi.nlm.nih.gov/pubmed/31692949
http://dx.doi.org/10.7573/dic.212606
work_keys_str_mv AT anguitamanuel clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies
AT delafigueramariano clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies
AT cabezaalejandroiperez clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies
AT fernandezcarmensuarez clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies